NDV-3A vaccination prevents C. albicans colonization of jugular vein catheters in mice

Sci Rep. 2019 Apr 17;9(1):6194. doi: 10.1038/s41598-019-42517-y.

Abstract

NDV-3A, a novel fungal vaccine undergoing clinical trials, contains a recombinant version of the Candida albicans rAls3 N-terminus protein (rAls3p-N) in aluminum hydroxide. In a Phase 1b/2a clinical trial, NDV-3A protected women from recurrent vulvovaginal candidiasis. Here, we reveal that active immunization in mice with NDV-3A induces high titers of anti-rAls3p-N antibodies that interfere with C. albicans ability to adhere to and invade endothelial cells, and form biofilm in vitro. Anti-rAls3p-N antibodies also significantly inhibit yeast dispersal from the hyphal layers of biofilms. Compared to placebo, NDV-3A vaccination inhibited C. albicans dissemination to kidneys and prevented colonization of central venous catheters in mice. Overall, these preclinical studies suggest that NDV-3A may serve as an immunotherapeutic strategy for prevention of infections on indwelling medical devices.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Animals
  • Antibodies, Fungal / immunology
  • Antibodies, Fungal / pharmacology*
  • Biofilms / drug effects
  • Candida albicans / drug effects
  • Candida albicans / immunology
  • Cell Adhesion / drug effects
  • Central Venous Catheters / microbiology
  • Fungal Proteins / immunology*
  • Fungal Vaccines / pharmacology
  • Fungal Vaccines / therapeutic use*
  • Humans
  • Infection Control
  • Mice
  • Recombinant Proteins
  • Vaccination / methods*

Substances

  • ALS3 protein, Candida albicans
  • Antibodies, Fungal
  • Fungal Proteins
  • Fungal Vaccines
  • Recombinant Proteins